ABN Amro Investment Solutions Invests $186,000 in Haemonetics Corporation $HAE

ABN Amro Investment Solutions purchased a new stake in shares of Haemonetics Corporation (NYSE:HAE) in the 3rd quarter, HoldingsChannel.com reports. The firm purchased 200,000 shares of the medical instruments supplier’s stock, valued at approximately $186,000.

A number of other large investors also recently bought and sold shares of the stock. River Road Asset Management LLC grew its stake in shares of Haemonetics by 18.7% during the 2nd quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock worth $122,586,000 after purchasing an additional 260,624 shares during the period. Geode Capital Management LLC grew its position in Haemonetics by 1.9% during the second quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock valued at $92,873,000 after buying an additional 23,257 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in Haemonetics by 11.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,060,790 shares of the medical instruments supplier’s stock valued at $51,777,000 after buying an additional 111,307 shares in the last quarter. SG Capital Management LLC increased its holdings in Haemonetics by 92.5% in the second quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock valued at $67,663,000 after buying an additional 435,660 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH raised its position in shares of Haemonetics by 36.2% in the third quarter. Fort Washington Investment Advisors Inc. OH now owns 706,312 shares of the medical instruments supplier’s stock worth $34,426,000 after acquiring an additional 187,630 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

HAE has been the subject of a number of recent analyst reports. Mizuho cut their price objective on Haemonetics from $90.00 to $80.00 and set an “outperform” rating for the company in a research report on Friday, February 6th. JPMorgan Chase & Co. upped their price objective on shares of Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a research report on Friday, December 12th. Raymond James Financial reaffirmed an “outperform” rating and set a $90.00 price objective on shares of Haemonetics in a report on Friday, November 14th. BTIG Research reissued a “buy” rating and set a $88.00 target price on shares of Haemonetics in a research note on Friday, February 6th. Finally, CJS Securities raised shares of Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $84.44.

Haemonetics Price Performance

Shares of HAE stock opened at $58.58 on Wednesday. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15. The company has a market capitalization of $2.72 billion, a PE ratio of 16.14, a price-to-earnings-growth ratio of 1.21 and a beta of 0.28. The firm’s 50-day moving average is $73.40 and its two-hundred day moving average is $64.21. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $87.32.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.04. The business had revenue of $338.97 million during the quarter, compared to analysts’ expectations of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.